About this trial

In this protocol, a combination of MRI, blood, and cerebrospinal fluid (CSF) analysis will be used to understand the natural history, underlying immunologic mechanisms, and clinical implications of central nervous system (CNS) lesions, in particular lesions in the cerebral cortex, in multiple sclerosis (MS) and other inflammatory and autoimmune disorders affecting the CNS. Patients with these disorders, as well as healthy controls, will undergo baseline clinical evaluation and testing, bloodwork, and MRI, with follow up clinical evaluation, bloodwork, and MRI at years 1, 3, and 6. Additional MRIs may be performed in patients with possible new lesion formation or to compare MRI techniques. Lumbar puncture will be performed on participants who are not currently being treated with disease modifying therapies and who are willing to undergo the procedure.

Eligibility criteria

Qualifiers

18 years old

able to provide consent in English

able to undergo MRI

Disqualifiers

contraindication to MRI

pregnancy

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

170 Participants
are grouped into 3 trial groups

Locations

1
Mount Sinai Hospital10029, New YorkNew York, United States

Sponsors and collaborators

Icahn School of Medicine at Mount Sinai

Lead sponsor